DoMore Diagnostics and PathAI form commercial partnership making Histotype Px® Colorectal available on AISight™

 
 

OSLO – November 19, 2024 – Histotype Px® Colorectal will be added to AISight™¹, the Image Management System for Digital Pathology from PathAI. Together, PathAI and DoMore Diagnostics will deploy Histotype Px to improve patient outcomes with AI-powered technology making precision medicine and personalized treatment available to cancer patients on a global scale.

Dr. Eric Walk, Chief Medical Officer at PathAI said:

“As part of our overall AISight Image Management System strategy, it is important for PathAI to make the most relevant, value-generating algorithms available on our platform. The DoMore Diagnostics Histotype Px Colorectal biomarker, with its growing body of evidence, has the potential to enhance the speed, accuracy, and quality of personalized treatment decisions for colorectal cancer patients.”

“DoMore Diagnostics and PathAI have a shared vision to realize the promise of digital pathology and outcome prediction to improve the lives of patients worldwide,” said Dr. Torbjørn Furuseth, Co-Founder and CEO of DoMore Diagnostics. “The AISight platform is set to spearhead innovations in the field going forward and will be a key partner as we continue our mission to personalize cancer treatment for patients worldwide with our Histotype Px digital biomarker.”

Press release can be found here.

¹AISight is for Research Use Only in the US; AISight Dx is CE-IVDR in Europe and UKCA in UK

About DoMore Diagnostics

DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.

About Colorectal Cancer and Histotype Px® Colorectal

Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.

Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.

For more information, please visit:

www.domorediagnostics.com
LinkedIn
The Lancet publication
The Lancet Oncology publication

Contact:

Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com

Previous
Previous

DoMore Diagnostics welcomes Dr. Lao Saal as our new consulting Medical Director

Next
Next

DoMore Diagnostics and Erasmus MC Cancer Institute Announce Collaboration to Validate Digital Biomarker Histotype Px® Colorectal for Personalized Cancer Treatment in Rectal Cancer Patients